NCT00555828View on ClinicalTrials.gov

Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Myocardial Infarction
Interventions
GENETIC

Allogeneic Mesenchymal Precursor Cells (MPCs)

25 M allogeneic MPCs by transendocardial injection

PROCEDURE

Standard-of-care treatment with NOGA® mapping and staged injections.

Standard-of-care treatment with NOGA® mapping and staged injections.

GENETIC

Allogeneic Mesenchymal Precursor Cells (MPCs)

75 M allogeneic MPCs by transendocardial injection

PROCEDURE

Standard-of-care treatment with NOGA® mapping and staged injections.

Standard-of-care treatment with NOGA® mapping and staged injections.

GENETIC

Allogeneic Mesenchymal Precursor Cells (MPCs)

150 M allogeneic MPCs by transendocardial injection

PROCEDURE

Standard-of-care treatment with NOGA® mapping and staged injections.

Standard-of-care treatment with NOGA® mapping and staged injections.

Trial Locations (2)

77030

RECRUITING

Texas Heart Institute/St. Luke's Hospital, Houston

55407-1139

RECRUITING

University of Minnesota/Minneapolis Heart Institute, Minneapolis

Sponsors

Lead Sponsor

Angioblast Systems
All Listed Sponsors
lead

Angioblast Systems

INDUSTRY

NCT00555828 - Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter